Andrew Leuchter

Andrew Leuchter, M.D. is Professor of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine at UCLA, where he also serves as Director of the Quantitative Electroencephalography (QEEG) Laboratory within the Semel Institute for Neuroscience and Human Behavior. A practicing physician-scientist, he has spent over three decades translating neurophysiological discoveries into innovative neuromodulation treatments for major depressive disorder, obsessive-compulsive disorder, tobacco use disorder, Alzheimer’s disease, chronic pain, and other neuropsychiatric conditions.

Education & Training: While specific degrees and institutions are not detailed in the supplied materials, Dr Leuchter’s extensive publication record and faculty appointment indicate completion of medical school, psychiatry residency, and research fellowship training leading to board certification and academic tenure.

Research Focus: Dr Leuchter’s work centers on the development of quantitative EEG biomarkers that predict treatment response and guide individualized neuromodulation. He pioneered the cordance method for assessing regional brain perfusion and metabolism and has led landmark clinical trials testing repetitive transcranial magnetic stimulation (rTMS), theta-burst stimulation (TBS), deep TMS coils, and trigeminal nerve stimulation (TNS). His recent investigations explore multi-locus rTMS protocols, resonant-frequency targeting, and the influence of age, sex, and comorbidities on treatment outcomes.

Clinical Impact: Findings from his trials have informed FDA approvals and international guidelines for non-invasive brain stimulation. Dr Leuchter collaborates across disciplines—integrating neuroimaging, neurochemistry, genetics, and computational neuroscience—to advance precision psychiatry and improve real-world effectiveness of antidepressant and anti-addiction therapies.

Scientific Awards & Honors: Although explicit awards are not listed in the text provided, Dr Leuchter’s sustained NIH funding, directorship of a core UCLA laboratory, and authorship of high-impact papers in Brain Stimulation, Neuropsychopharmacology, and American Journal of Psychiatry underscore recognition as a leading authority in neurophysiology-guided neuromodulation.

Research Support & Leadership: He oversees the QEEG Core Laboratory that services multiple federally funded studies, mentors trainees in psychiatry and neuroscience, and serves as principal investigator on industry, foundation, and NIH grants investigating novel stimulation paradigms for treatment-resistant mood and cognitive disorders.